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Abstract
Anogenital malignancy has a significant association with high-risk mucosal alpha-human papillomaviruses (alpha-PV),
particularly HPV 16 and 18 whereas extragenital SCC has been linked to the presence of cutaneous beta and gamma–HPV
types. Vulval skin may be colonised by both mucosal and cutaneous (beta-, mu-, nu- and gamma-) PV types, but there are
few systematic studies investigating their presence and their relative contributions to vulval malignancy. Dysregulation of
AKT, a serine/threonine kinase, plays a significant role in several cancers. Mucosal HPV types can increase AKT
phosphorylation and activity whereas cutaneous HPV types down-regulate AKT1 expression, probably to weaken the
cornified envelope to promote viral release. We assessed the presence of mucosal and cutaneous HPV in vulval malignancy
and its relationship to AKT1 expression in order to establish the corresponding HPV and AKT1 profile of normal vulval skin,
vulval intraepithelial neoplasia (VIN) and vulval squamous cell carcinoma (vSCC). We show that HPV16 is the principle HPV
type present in VIN, there were few detectable beta types present and AKT1 loss was not associated with the presence of
these cutaneous HPV. We show that HPV16 early gene expression reduced AKT1 expression in transgenic mouse epidermis.
AKT1 loss in our VIN cohort correlated with presence of high copy number, episomal HPV16. Maintained AKT1 expression
correlated with low copy number, an increased frequency of integration and increased HPV16E7 expression, a finding we
replicated in another untyped cohort of vSCC. Since expression of E7 reflects tumour progression, these findings suggest
that AKT1 loss associated with episomal HPV16 may have positive prognostic implications in vulval malignancy.
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Introduction
Human papillomaviruses (HPV) are a family of over 120 small
double-stranded DNA viruses with mucosal or cutaneous
epitheliotropism [1]. The mucosal alpha-papillomavirus (alpha-
PV) genus contains high-risk HPV types, such as HPV 16 and 18,
which are causal in cervical intraepithelial neoplasia (CIN) and
cervical cancer [2]. Cutaneous beta-PVs are ubiquitous in skin and
hair follicles. They are associated with cutaneous squamous cell
carcinoma (SCC) development in the genodermatosis epidermo-
dysplasia verruciformis and may also act as co-factors with
ultraviolet radiation (UVR) in the pathogenesis of cutaneous SCC
arising outside the context of EV, particularly in immunosup-
pressed individuals [3]. However recent RNA sequencing analysis
of SCCs has put the role of beta-papillomaviridae into question
[4]. Cutaneous mu-, nu- and gamma-PV genuses have also been
implicated in causing benign and malignant humans skin lesions
[3]. Although less common than cervical cancer, vulval squamous
cell carcinoma (vSCC) and its precursor, vulval intraepithelial
neoplasis (VIN), are increasing in incidence [5]. High-risk alpha-
PVs may play an oncogenic role as approximately 60% of VIN are
alpha-PV DNA positive [6,7]. VIN may be classified into the usual
or undifferentiated type (uVIN) associated with HPV and
differentiated VIN (dVIN) associated with the chronic inflamma-
tory dermatosis, lichen sclerosus (LS), and regarded as non-HPV
mediated [8].
AKT1 is one of 3 isoforms of the AKT family of serine/
threonine kinases. AKT1 induces protein synthesis and has a role
in normal cellular growth. It also inhibits apoptosis and its
dysregulation plays a significant role in several cancers [9].
Cervical cancer progression is accompanied by increased expres-
sion of the HPV E7 oncoprotein. E7 causes pleiotropic effects on
cell cycle progression and inhibition of apoptosis [10]. We have
previously shown that in extragenital cutaneous viral warts, HPV
infection is associated with loss of expression of AKT1 in the upper
granular layer of the epidermis [11]. This contrasts with the
oncogenic E7 early gene from high-risk alpha-PVs such as HPV16
and beta-PVs which up-regulate a lower suprabasal AKT activity
[12,13]. Loss of AKT1 in non-genital warts causes changes in
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cornified envelope structure that we postulate are required for
HPV virions to escape from the cornified envelope [11,13]. The
HPV types associated with this loss have not yet been clearly
defined, although expression of the complete early region of
HPV8, a cutaneous beta-PV, in mouse epidermis, or the
expression of HPV8 E2 in keratinocyte organotypic cultures
reduces AKT1 expression [11,14].
The nature of the HPV infection in VIN remains less well-
defined than in CIN, as does the mechanism by which HPV
contributes to the risk of the lesion becoming an invasive SCC. We
hypothesised that VIN have a higher prevalence of non-alpha-PV
types compared to cervix and that combined effects of alpha and
beta-PV types result in pathogenic mechanisms of VIN distinct
from those in cervical dysplasia. In contrast, high-risk alpha
papillomaviridae (HPV16), was the prevalent subtype in our VIN
cohort. AKT1 loss correlated with episomal, high copy number
HPV16 infection, while low copy number and integration events
and high levels of the E7 oncoprotein correlated with normal levels
of AKT1 expression.
Materials and Methods
Patients and samples
Clinical material was obtained from immunocompetent patients
attending the dermatology and specialist vulval oncology clinics at
Barts and the London NHS Trust. Routine histopathologic
evaluation, hematoxylin-eosin, was performed on formalin-fixed
lesional sections. Both formalin fixed sections and samples snap-
frozen in liquid nitrogen and stored at 280uC were analysed in
this study. Ethical approval for this investigation was obtained
from the East London and City Health Authority local ethics
committee and the study was conducted according to the
Declaration of Helsinki Principles. All patients participating in
the study provided written, informed consent. Cervical tissue
sections were obtained from Biomax US (Rockville, US). Ear
epidermal sections were obtained from 3 different 6 month old
K14-HPV16 complete early region mice [15].
Immunohistochemistry
Immunohistochemistry was performed on formalin fixed paraffin-
embedded tissue sections using standard techniques. Primary
antibodies used were as follows: rabbit anti-Akt1 (Cell Signaling
Technologies, Danvers, USA) 1:50; rabbit anti-keratin 1 (Covance,
Cambridge, UK) 1:500; rabbit anti-loricrin (Covance, Cambridge,
UK) 1:500; mouse anti HPV16E7 1:50 (Santa Cruz Biotechnologies,
Santa Cruz, US); Mouse anti HPV16E1ˆE4 (Santa Cruz Biotechnol-
ogies, Santa Cruz, US). Antibody detection was by the Elite Avidin-
Biotin-Complex system and DAB (Vector Laboratories, Burlingame,
US) using the appropriate conjugated secondary antibodies (Vector
Laboratories, Burlingame, US). Sections were counterstained in
haemotoxylin. Images were taken with a Leica DMLB microscope
with a x20 (NA 0.4) objectives, using a Q imaging digital camera with
QCapture software (Qimaging, Surrey, Canada).
HPV detection and genotyping by degenerate and
nested PCR and copy number evaluation
Mucosal alpha-PV genotyping was performed on both formalin
fixed sections and samples snap-frozen in liquid nitrogen using a
technique suitable for poor quality, degraded DNA. Other HPV
genotyping and copy number analysis were restricted to samples
snap-frozen in liquid nitrogen because of a prerequisite for good
quality DNA. Detection of mucosal alpha-PV was performed by
PCR using the SPF10 primer set [16], which amplifies a small
fragment of 65 bp within the L1 open reading frame, with typing
by reverse hybridisation assay (HPV SPF10 LiPA kit, Labo Bio-
Medical Products, Rijswijk, Netherlands). Detection of mu/nu-PV
and muco-cutaneous species 4 alpha-PV was performed using
nested and degenerate PCR to the L1 open reading frame with
typing by sequencing as described previously [17], specifically
CN1F/CN1R primers nested within HVP2/B5 for mu/nu
(including HPV1, 41 and 63) and CN2F/CN2R nested within
HVP2/B5 for muco-cutaneous species 4 alpha-PV (including
HPV 2,27,57). All beta-PV were detected using the PM primer set
[18], which amplifies a 117 bp fragment from the E1 open reading
frame, with typing by reverse hybridisation assay (RHA kit skin
(beta) HPV detection system, Diassay, Rijswijk, Netherlands).
HPV16 copy number was analysed according to the protocol of
Weissenborn et al., [19].
PCR analysis of HPV16 E1-E2 and E7 genomic regions
Standard PCR was performed on DNA from the frozen VINs to
a region encompassing the E1 and E2 early gene region, Forward
primer -59-ATGGTACAATGGGCCTACGATAATG-39, Re-
verse primer -59-CGTCTGTGTTTCTTCGGTGC. Product
size, 1522 bp, a second primer pair amplifying a 1.2 kb fragment
of the Alpha-1 antitrypsin gene was used to confirm DNA
integrity. Forward primer -59 -CGACGAGAAAGGGACT-
GAAG, Reverse primer -59 - GACAGCAACAGGCACAAAGA.
E7 genomic PCR was performed on DNA extracted from paraffin
embedded sections of the vSCCs to confirm the results of HPV
SPF10 LiPA analysis. Forward primer 1 59- ACTC-
TACGCTTCGGTTGTGC, reverse primer 1 - 59 - TGCCCAT-
TAACAGGTCTTCC. Product size 72 bp. Forward primer 2 59 -
ACAAGCAGAACCGGACAGAG, reverse primer 2 59 - GCA-
CAACCGAAGCGTAGAGT. Product size 76 bp.
Statistical analysis
Correlations between viral presence, HPV copy number,
integration status and AKT1 loss were determined using the
Fisher’s exact test. An unpaired T-test was used to determine
significance of changes in HPV16 copy number. A Mann-Whitney
U test was used to determine the association between between
AKT1 expression and HPV16E7 immunohistochemistry score in
the untyped samples.
Results
Expression of AKT1 is identical in vulval and non-genital
skin
We compared the expression of AKT1 and loricrin (a
differentiation marker expressed in the upper epidermal granular
layer) in normal extragenital cutaneous, cervical and vulval
epithelia (Figure 1). Extragenital and vulval epidermis had
identical expression patterns of AKT1 and loricrin, with expres-
sion of both proteins being restricted to the granular layer [13]. In
contrast, neither AKT1 nor loricrin were detected in the upper
cervical epithelium. Cytokeratin 1 was expressed in all suprabasal
layers of all three epithelia. These findings suggest that the
squamous keratinising epithelial component of vulval skin is
similar to extragenital epidermis and may therefore be similarly
susceptible to infection by cutaneous HPV types as well as alpha
(mucosal) high risk HPV types.
No correlation between either Beta-PV or HPV16 and
AKT1 loss
We wanted to establish whether AKT1 is down-regulated
similar to non-genital skin or up-regulated, potentially due to
HPV and AKT1 in Vulval Intraepithelial Veoplasia
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alpha-PV. We therefore analysed HPV types present in 14 snap-
frozen high-grade VIN (Histological grade 2 and 3) (Table 1),
correlating this with AKT1 loss. AKT1 expression was examined
by immunohistochemistry ([13]; Figure 2A). AKT1 was lost in 6/
14 (42%) of VIN, and HPV16 was present in 11/14 (78%)
samples. Five of the 6 (83%) AKT1 negative VIN were HPV16
positive, while 6/8 (75%) of AKT1 positive VIN were HPV16
positive (n.s., Fishers exact test). Beta-PV types were detected in 2/
14 (14%, one AKT1 positive, one AKT1 negative, Table 1).
Although the RHA assay is non-quantitative, the weakness of the
beta-PV signals compared to HPV16 signals was consistent with
beta-PV being present at very low copy number (data not shown).
Note that no other HPV types were detected by this analysis (data
not shown). We concluded that beta-PV were unlikely to be
significant aetiological agents in VIN.
HPV16 early gene expression reduces granular layer AKT1
expression
We used a transgenic mouse model to investigate whether the
HPV16 early gene region causes AKT1 loss in the granular layer
in a similar manner to the HPV8 complete early gene region [11].
Granular layer AKT1 expression was down-regulated in the non-
lesional ear epidermis of the 6 month old mouse expressing the full
length HPV16 complete early region under the control of the
keratin 14 promoter ([15]; Figure 2B). The epidermis was
hyperproliferative, unlike keratin 14-HPV8 early region transgenic
mouse non-lesional epidermis [14]. Hyperproliferation in the K14-
HPV16 mouse has been reported previously [15].
AKT1 loss correlated with episomal HPV16 in VIN and
predicted integration events correlated with increase in
HPV16E7 expression
To determine whether integration events correlated with
changes in early gene expression, we examined 8 VIN for
HPV16 E7 and E1ˆ E4 expression. HPV16 E7 is normally up-
regulated after integration of HPV16 [20]. HPV16 E1ˆ E4
accumulates in mitochondria, clumping them in a region close
to the nucleus [21] and on HPV16 integration is frequently
truncated causing nuclear accumulation [22]. In HPV16 and
AKT1 positive VIN, E7 expression was high and widespread not
only in the nucleus, as has been reported previously in cervical
cancer, but also in the cytoplasm in some VIN [23]. E1ˆ E4
expression was widespread and nuclear. In HPV16 positive and
AKT1 negative VIN, E7 expression was lower and E1ˆ E4 was
restricted to the perinuclear region in a few cells (Figure 3)
suggesting again that AKT1 positivity correlates with life cycle
events consistent with HPV16 integration in VIN.
As AKT1 loss was only detected in a subset of HPV16 positive
VIN, we investigated whether this correlated with the physical
status (episomal versus integrated) of the viral genome; we
hypothesise that only episomal HPV16 is capable of lifecycle
completion which concomitantly requires AKT1 down-regulation
[11]. HPV16 copy number was increased on average 16-fold in
AKT1 negative VIN (Figure 4A). The average copy number per
cell in AKT1 positive VIN was less than 1, suggestive of genome
integration [24]. We tested for HPV16 integration in the 11
HPV16 positive VIN by PCR using primers encompassing the E1
and E2 genes of HPV16 (Figure 4B), whose loss correlates with an
integrated viral genome [25]. PCR product was detected in 4/5
(80%) of the AKT1 negative, HPV16 positive VIN tested,
compared with 1/6 (17%) of the AKT1 positive, HPV16 positive
VIN (p= 0.08, Fishers Exact Test). An alpha-1 antitrypsin PCR
product was detected in all E1-E2 negative samples, suggesting
that these negative results were not due to lack of DNA integrity.
Although not reaching significance, this suggested that HPV16
was more likely to be integrated in the AKT1 positive VIN.
AKT1 loss correlated with low expression of HPV16 E7 in
a vSCC cohort
To determine the diagnostic significance that AKT1 loss may
have in assessing the progression or severity of VIN, we examined
another series of 30 paraffin embedded vSCC for both AKT1 loss
and HPV16 E7 protein expression. AKT1 loss occurred in 12/30
(40%) of the samples consistent with the first set of samples. Again,
as with the first set of samples, AKT1 negative vSCC had
significantly lower E7 staining scores than AKT1 positive VIN
(p= 0.003, Mann-Whitney U test, Figure 5, and Table S1).
Discussion
This is the first study to examine the prevalence of both
cutaneous and mucosal HPV in vulval malignancy and to
correlate the status of HPV16 with AKT1 expression. In a cohort
of VIN, we found that that AKT1 loss correlated with the presence
of high copy number, episomal HPV16. When AKT1 and HPV16
were both present, this was associated with integration events, with
a high level of HPV16E7 expression and altered localisation of the
E1ˆE4 protein. Our data suggests a model in which HPV16
expression in the external vulval epithelium is episomal at first.
AKT1 is down-regulated at this time by the E2 protein [11], to
weaken the cornified layer to allow for continued rounds of
papillomavirus infection. Subsequently the HPV16 genome is
disrupted by integration, normally at the site of the E1 and E2
early genes, restoring AKT1 expression. These data and analysis
of our untyped vSCC cohort indicated that restoration of AKT1
expression correlated with up-regulation of HPV16 E7.
Figure 1. Keratinocyte differentiation marker expression in
epidermis, vulva and cervix. Immunohistochemical analysis of
AKT1, loricrin and keratin 1 expression in extragenital cutaneous
epidermis, vulval external epithelium and cervix. Bar 50 mm.
doi:10.1371/journal.pone.0038608.g001
HPV and AKT1 in Vulval Intraepithelial Veoplasia
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HPV16 are highly prevalent HPV in vulval malignancy,
while beta papillomaviruses do not play a role in
malignant progression
The prevalence of different HPV types by analysis of HPV
DNA in vulval SCC differs significantly from those reported in
previous studies of SCC at extragenital cutaneous sites by our
group and other researchers using the same and alternative
methodologies [3,26]. Compared with our previous findings using
the same methodology in cutaneous SCC and carcinoma in situ
which is equivalent to VIN [27], there was a higher prevalence of
mucosal alpha-PVs (79% in vulva compared with 8.5% cutaneous
CIS/SCC% in extragenital skin). Beta-PVs prevalence was much
Figure 2. AKT1 expression is lost in a subset of VIN and the epidermis of the K14-HPV16mouse. A. Histology and AKT1 expression in two
representative VIN. Inset shows specific AKT1 expression associated with nucleated upper epidermal cells. Secondary alone control of upper
epidermis is also shown. B. Immunohistochemical analysis of AKT1 in the dorsal epidermis of the K14-HPV8 complete early region (CER) and ear
epidermis of the K14-HPV16 complete early region mouse and corresponding wildtype controls (wildtype). Arrowheads indicate AKT1 positivity in the
granular layer of controls. Sec alone is a no primary antibody control for staining specificity. Bar (A–B) 50 mm.
doi:10.1371/journal.pone.0038608.g002
Table 1. Summary of nested PCR analysis and sequencing for HPV16/18, and Beta-PV types.
DIAGNOSIS MY11_GP6 Mu/Nu Alpha 4 Beta Akt1
Copy
No
E1-E2
PCR Positive E1-E4 E7
KGV02 VIN3, AIN3 HPV16 2 +++ 2 neg 7.7 yes n.d. n.d.
KGV05 VIN and LS HPV16 2 +++ + neg 10.9 yes low low
KGV08 VIN2 HPV16 2 +++ 2 neg 5 yes low low
KGV11 VIN3 HPV16 2 +++ 2 neg 0.36 no high high
KGV29 VIN3 - 2 2 2 neg n.d. n.d. n.d. n.d.
KGV36 LS and VIN HPV16 2 2 2 neg 11.7 yes n.d. n.d.
KGV01 VIN3 HPV16 2 +++ 2 pos 0.44 no high high
KGV03 VIN3 HPV16 2 +++ 2 pos 0.51 no high high
KGV10 VIN HPV16 2 + + pos 0.14 no high high
KGV21 VIN3 HPV16 2 2 2 pos 1.3 no n.d. n.d.
KGV33 VIN3 - 2 2 2 pos n.d. n.d. n.d. n.d.
KGV37 VIN HPV16 2 +++ 2 pos 0.2 no n.d. n.d.
KGV40 VIN and AIN - 2 2 2 pos n.d. n.d. n.d. n.d.
KGV48 VIN HPV16 2 2 2 pos 0.67 yes high high
-, sample is negative for this PV-type. AKT1 indicates the presence (pos) or absence (neg) of AKT1 expression in the epidermis of the VIN/vSCC. Copy no. indicates the
HPV16 copy number per cell in each sample. Integrated? denotes the integration status of HPV16 based on the HPV16 genomic PCR. N.B. Several samples were PCR-
positive for cutaneous alpha-PV species 4, however sequencing showed this was due to non-specific amplification of HPV16 in all cases; gamma and mu/nu types were
not detected. E1-E4 and E7, summary of the immunohistochemistry for HPV16 E1ˆE4 and E7. n.d – not determined.
doi:10.1371/journal.pone.0038608.t001
HPV and AKT1 in Vulval Intraepithelial Veoplasia
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e38608
lower in the vulva (14% versus 57.4% respectively). Our study
suggests that based on the relatively low amounts of beta-HPV
DNA detected by the reverse hybridisation assays, beta-HPV types
do not play a significant role in vulval malignancy, consistent with
previous analyses of beta-HPV presence in anogential plucked
hairs [28].
Episomal HPV16 correlates with AKT1 loss – Significance
for HPV16 lifecycle in external epithelia
Although the expression of the HPV16 complete early region in
epidermis can cause carcinogenesis [15], whether or not HPV16
can progress through lifecycle and produce virions in external
(cutaneous) epithelia has yet to be determined. The data presented
here suggests that HPV16 is able to progress through stages of its
lifecycle, and can be retained episomally in the epidermis, as
demonstrated indirectly by the loss of AKT1 and directly by the
detection of the intact HPV16 E1-E2 genomic region. AKT1
expression was lost in 88% of non-genital warts [11] while in this
study AKT1 was lost in 42% of VIN. This suggests that HPV16
more readily integrates in external epithelia, than other cutaneous
resident viruses. We would therefore expect HPV16 infected
external epithelia to more rapidly become malignant. Consistent
with this concept, the mean time of tumour formation in the K14-
HPV16 complete early region mouse is 3 fold less than that of the
K14-HPV8 complete early region mouse [14,15].
Average episomal HPV16 copy number was less than 10 per
cell in the whole of the VIN cohort, compared to CIN where the
mean copy number is over 2000 [29]. In high grade CIN, there is
high HPV16 copy number as well as an increased frequency of
integrants (40%,[30]). In contrast, in high grade VIN very low
HPV16 copy number per cell correlated with our hallmarks of
integration – nuclear E1-E4 expression, high E7 expression and
Akt1 retention. The integration frequency in high grade VIN was
higher than in high grade CIN–54% in our typed cohort and,
based on AKT1 expression, 60% in our untyped cohort. One
possible interpretation of these data is that HPV16 integrates more
Figure 3. Early gene expression in VIN. Expression of the early genes 16E1ˆE4 and 16E7 in a representative AKT1 negative (AKT1 2ve) and AKT1
positive (AKT1 +ve) VIN. Note the increased 16E7 expression in AKT1 positive VIN, and the change of 16E1ˆE4 expression from perinuclear low
expression in AKT1 negative VIN to high nuclear expression in AKT1 positive VIN (see insets). Bar 50mm.
doi:10.1371/journal.pone.0038608.g003
Figure 4. Copy number and integration analysis of VIN. A. Copy number analysis of HPV16 DNA in AKT12ve (p = 5) and AKT +ve (p = 6) VIN. *,
p = 0.006 (unpaired T-test). B. PCR of DNA for a region encompassing the HPV16 E1 and E2 genes in the 14 VIN, and the relationship with AKT1 loss in
the VIN. L. 250 bp DNA ladder, W, no DNA control.
doi:10.1371/journal.pone.0038608.g004
HPV and AKT1 in Vulval Intraepithelial Veoplasia
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frequently as it is not able to efficiently produce high copy number
virus in external keratinocytes.
In the cervix during progression to CIN and SCC, the
expression of E7 is widespread and nuclear [20]. However in
the external vulval epithelium, we observed cytoplasmic staining of
HPV16 E7. Although there is little or no data on normal
expression of cutaneous HPV E7, it may be that the expression
pattern seen for HPV16E7 in VIN is normal. Transport of the E7
protein from the nucleus to the cytoplasm is mediated by a novel
Ran-dependent nuclear export [23]. It is possible that in the
epidermis, this export pathway is more prevalent than nuclear
import, leading to increased cytoplasmic E7 expression in the
epidermis. It would be interesting to examine the differences in
gene expression between keratinocytes expressing nuclear
HPV16E7 and cytoplasmic HPV16E7 to understand how this
may relate to differences in HPV16 lifecycle and integration in the
external vulval epithelium versus the cervix.
In summary, we show that cutaneous beta-PV are not
significantly associated with vulval neoplasia, and that HPV16,
when episomal, can reduce AKT1 expression. We propose that
AKT1 expression status may therefore represent a potential
prognostic biomarker in VIN. However, a larger study monitoring
AKT1 expression with integration status and viral load over time
would be required to determine whether AKT1 loss does indeed
correlate with prognosis.
Supporting Information
Table S1 Summary of AKT1 and E7 antibody staining
and L1 and E7 PCR for HPV16. Summary of Immunohisto-
chemistry and PCR on the vSCC cohort. AKT1 staining and PCR
are scored positive or negative as in table 1. HPV16 E7
immunohistochemistry was scored from 0–3, where 0, is no
staining, while 3 is high and widespread staining throughout the
sample. PCR analysis of both HPV16L1 and two regions of
HPV16E7 showed conflicting data and therefore HPV status
could not be reliably ascertained using this method.
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